Treatment of herpes zoster with topical tetracaine
AssigneePagari Life Science Corp
InventorsAlan J. Wickenhauser, Stephen E. Peipert
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating herpes zoster (shingles), such as in the acute eruptive phase, comprising topically administering tetracaine base (or a pharmaceutically acceptable salt thereof) to a patient in need of such treatment.
Claims26
(canceled)
(canceled)
A method of treating herpes zoster in the active eruptive phase in a patient in need thereof comprising topically administering to the patient a composition comprising from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, based on the 100% total weight of the composition.
A method of treating lesions associated with herpes zoster in the active eruptive phase in a patient in need thereof comprising topically administering to the patient a composition comprising (i) from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, based on the 100% total weight of the composition, wherein an effective amount of the composition is administered to treat the lesions associated with herpes zoster in the active eruptive phase.
A method of treating one or more symptoms associated with herpes zoster in the active eruptive phase in a patient in need thereof comprising topically administering to the patient a composition comprising (i) from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, based on the 100% total weight of the composition, wherein an effective amount of the composition is administered to treat the one or more symptoms associated with herpes zoster in the active eruptive phase.
A method of treating herpes zoster in the active eruptive phase in a patient in need thereof comprising topically administering to the patient a composition comprising from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, based on the 100% total weight of the composition, wherein the composition comprises a carrier comprising a non-aqueous vehicle, and the non-aqueous vehicle comprises a high molecular weight poly(ethylene oxide) homopolymer, a cellulose polymer, propylene glycol and a plasticized hydrocarbon gel.
Dependencies are inferred from the claim text.